Brian I Carr
Overview
Explore the profile of Brian I Carr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
183
Citations
2955
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carr B, Bag H, Yilmaz S
Ann Gastroenterol Dig Syst
. 2024 Jun;
7(1).
PMID: 38887309
Background: The factors responsible for hepatocellular carcinoma (HCC) growth are not precisely known. Aims: To study the clinical parameters associated with increases in maximum tumor diameter (MTD). Methods: A new...
2.
Carr B, Bag H, Ince V, Isik B, Baskiran A, Yilmaz S
Hepatol Forum
. 2024 Mar;
5(2):77-86.
PMID: 38487742
Background And Aim: Patients with hepatocellular carcinoma (HCC) are managed in various hospital departments, which complicates the assessment of the overall picture. In our large liver transplant institute, we evaluate...
3.
Garzali I, Carr B, Ince V, Isik B, Akatli A, Yilmaz S
Turk J Gastroenterol
. 2024 Mar;
35(2):143-149.
PMID: 38454246
Background/aims: Hepatocellular carcinoma is the main type of primary liver cancer. Macroscopic vascular invasion is usually identified during imaging, whereas microvascular invasion is usually determined by histopathological evaluation. We aim...
4.
Carr B, Rui F, Ince V, Yilmaz S, Zhao X, Feng Y, et al.
Portal Hypertens Cirrhosis
. 2024 Jan;
2(4):165-170.
PMID: 38179146
Aims: There are many studies on the incidence of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC), but very little is known about the HCC features in different populations. The study...
5.
Carr B, Guerra V, Ince V, Isik B, Yilmaz S
Liver Res
. 2023 Oct;
7(3):256-262.
PMID: 37854945
Background And Aims: Hepatocellular carcinoma (HCC) is characterized by several clinically important prognostic parameters, including portal vein thrombosis (PVT), tumor multifocality, and serum alpha-fetoprotein (AFP) levels, in addition to maximum...
6.
Garzali I, Hargura A, Ince V, Varol F, Carr B, Yilmaz S
Turk J Gastroenterol
. 2023 Sep;
34(12):1235-1239.
PMID: 37681267
Background/aims: Liver transplantation is an acceptable treatment for some selected hepatocellular carcinoma. We report our experience of 6 patients with liver transplantation for hepatocellular carcinoma with background inherited metabolic disease....
7.
Carr B, Bag H, Akkiz H, Karaogullarindan U, Ince V, Isik B, et al.
Clin Pract (Lond)
. 2023 Aug;
19(4):1953-1958.
PMID: 37621527
Background: Large HCCs can often be associated with low levels of cirrhosis. However, inflammation is also regarded as a driver of HCC growth. Objectives: To compare patients with large >5...
8.
Kilci B, Ince V, Carr B, Usta S, Bag H, Samdanci E, et al.
Turk J Gastroenterol
. 2023 Jun;
34(7):753-759.
PMID: 37326153
Background/aims: The aim of this study is to evaluate the parameters that might be associated with pathologically diagnosed microvascular invasion and poor differentiation, using complete blood count and routine clinical...
9.
Carr B, Guerra V
Oncology
. 2023 Mar;
101(5):313-320.
PMID: 36878197
Introduction: Many single and combination blood tests that reflect local or systemic inflammation have been shown to be useful prognosticators in patients with a variety of tumor types. To try...
10.
Giacomelli L, Sacco R, Papa S, Carr B
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831584
Tumor stage definition is required for the description of the diagnosis and the development and use of treatment guidelines, as well as to enable clinical research (including clinical trials) and...